Effect of High Dose (10, 000 IU) Epoetin Alfa (Espogen(R)) Therapy in CAPD Patients.
- Author:
Ho Myoung YEO
1
;
Dae Joong KIM
;
So Yeon CHOI
;
Yeon Sil DO
;
Eun Hee JANG
;
Hyun Jeong BAEK
;
Min Ok KIM
;
Hyun Jin KIM
;
Jung Ah KIM
;
Wooseong HUH
;
Yoon Goo KIM
;
Ha Young OH
Author Information
1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. daejoongsmc.kim@samsung.com
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
CAPD;
Erythropoietin;
Anemia
- MeSH:
Anemia;
Erythropoietin;
Hematocrit;
Humans;
Peritoneal Dialysis;
Peritoneal Dialysis, Continuous Ambulatory*;
Random Allocation;
Epoetin Alfa
- From:Korean Journal of Nephrology
2005;24(3):441-447
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Recombinant human erythropoietin (rHuEPO) is an established treatment for renal anemia. We aimed to determine that high dose subcutaneous epoetin alfa is as efficient and safe as usual dose for treating anemia in peritoneal dialysis patient. METHODS: Twenty four patients on CAPD were randomly assigned to either 10, 000 IU (high dose group, n=12) or 4, 000 IU (usual dose group, n=12) epoetin alfa regimen with variable interval for 24 weeks. If hematocrit was out of range (30-39%), the interval was changed within 50% of previous interval. RESULTS: Mean hemoglobin levels at randomization and after 12 weeks and 24 weeks were 11.4+/-1.3, 11.3+/-1.1, and 11.6+/-1.2 g/dL in high dose group compared with 10.8+/-0.8, 11.5+/-1.1, and 10.9+/-1.2 g/dL in usual dose group (p<0.05). The mean weekly epoetin alfa dosages at randomization and after 12 and 24 weeks were 93.2+/-45.3, 95.5+/-33.6, and 102.5+/-43.6 IU/kg in high dose group compared with 78.8+/-29.4, 75.9+/-20.6 and 75.5+/-39.7 IU/kg in usual dose group (p<0.05). But, interval in high dose group was two times as longer as usual dose group. Adverse events were generally mild and transient CONCLUSION: This study demonstrates that epoetin alfa 10, 000 IU is as efficient and safe as 4, 000 IU with similar weekly dose in CAPD patients. epoetin alfa 10, 000 IU administration reduces frequency of injections about one half.
